Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S.

Ann Hematol. 2014 Feb;93(2):233-42. doi: 10.1007/s00277-013-1860-8.

PMID:
24563925
2.

Autologous stem cell transplantation in mantle cell lymphoma: a report from the SFGM-TC.

Touzeau C, Leux C, Bouabdallah R, Roussel M, Delarue R, Bouabdallah K, Thieblemont C, Cacheux V, Cartron G, Compain L, Gyan E, Morschhauser F, Casasnovas O, Moles MP, Michallet AS, Gressin R, Damaj G, Rose C, Sirvent A, Hermine O, Mohty M, Milpied N, Le Gouill S.

Ann Hematol. 2014 Feb;93(2):233-42. doi: 10.1007/s00277-013-1860-8. Epub 2013 Aug 16.

PMID:
23949376
3.

The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.

Dreger P, Martin S, Kuse R, Sonnen R, Glass B, Kröger N, Parwaresch R, Kneba M, Schmitz N, Haas R.

Hematol J. 2000;1(2):87-94.

PMID:
11920175
4.

Autologous stem cell transplantation in patients with mantle cell lymphoma.

Oinonen R, Jantunen E, Itälä M, Lehtinen T, Kuittinen O, Franssila K, Wiklund T, Elonen E.

Leuk Lymphoma. 2002 Jun;43(6):1229-37.

PMID:
12152990
5.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28.

6.

Early lymphocyte recovery after autologous stem cell transplantation predicts superior survival in mantle-cell lymphoma.

Joao C, Porrata LF, Inwards DJ, Ansell SM, Micallef IN, Johnston PB, Gastineau DA, Markovic SN.

Bone Marrow Transplant. 2006 May;37(9):865-71.

PMID:
16532015
7.

Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.

Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, Lacasce AS, Blum KA, Byrd JC, Kelly M, Stock W, Linker CA, Canellos GP.

J Clin Oncol. 2009 Dec 20;27(36):6101-8. doi: 10.1200/JCO.2009.22.2554. Epub 2009 Nov 16.

8.

Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.

Budde LE, Guthrie KA, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Maloney DG, Gopal AK.

J Clin Oncol. 2011 Aug 1;29(22):3023-9. doi: 10.1200/JCO.2010.33.7055. Epub 2011 Jul 5.

9.

Cytarabine, Ki-67, and SOX11 in patients with mantle cell lymphoma receiving rituximab-containing autologous stem cell transplantation during first remission.

Chakhachiro ZI, Saliba RM, Okoroji GJ, Korbling M, Alousi AM, Betul O, Anderlini P, Ciurea SO, Popat U, Champlin R, Samuels BI, Medeiros LJ, Bueso-Ramos C, Khouri IF.

Cancer. 2013 Sep 15;119(18):3318-25. doi: 10.1002/cncr.28219. Epub 2013 Jun 17.

10.

Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.

Mangel J, Buckstein R, Imrie K, Spaner D, Crump M, Tompkins K, Reis M, Perez-Ordonez B, Deodhare S, Romans R, Pennell N, Robinson JB, Hewitt K, Richardson P, Lima A, Pavlin P, Berinstein NL.

Semin Oncol. 2002 Feb;29(1 Suppl 2):56-69. Review.

PMID:
11842390
11.

CD34+ selected versus unselected autologous stem cell transplantation in patients with advanced-stage mantle cell and diffuse large B-cell lymphoma.

Berger MD, Branger G, Leibundgut K, Baerlocher GM, Seipel K, Mueller BU, Gregor M, Ruefer A, Pabst T.

Leuk Res. 2015 Jun;39(6):561-7. doi: 10.1016/j.leukres.2015.03.004. Epub 2015 Mar 19.

PMID:
25890431
12.

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V, Delaunay J, Chevallier P, Guillaume T, Blin N, Ayari S, Clavert A, Mohty M, Dousset C, Milpied N, Harousseau JL, Moreau P, Wuilleme S, Moreau A, Le Gouill S.

Transplantation. 2012 Aug 15;94(3):295-301.

PMID:
22797728
13.

Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.

Metzner B, Müller TH, Gebauer W, Casper J, Kraemer D, Rosien B, Schumann-Binarsch S, Thole R, Köhne CH, Dreyling M, Hoster E, Pott C.

Ann Hematol. 2014 May;93(5):803-10. doi: 10.1007/s00277-013-1976-x. Epub 2013 Dec 13.

PMID:
24337447
14.

Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.

Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK.

Ann Oncol. 2015 Nov;26(11):2323-8. doi: 10.1093/annonc/mdv364. Epub 2015 Sep 7.

PMID:
26347113
15.

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein NL.

Ann Oncol. 2004 Feb;15(2):283-90.

16.

High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.

Schaaf M, Reiser M, Borchmann P, Engert A, Skoetz N.

Cochrane Database Syst Rev. 2012 Jan 18;1:CD007678. doi: 10.1002/14651858.CD007678.pub2. Review.

PMID:
22258971
17.

LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre.

Perz JB, Giles C, Szydlo R, O'Shea D, Sanz J, Chaidos A, Wagner S, Davis J, Loaiza S, Marin D, Apperley J, Olavarria E, Rahemtulla A, Lampert I, Naresh K, Samson D, MacDonald D, Kanfer EJ.

Bone Marrow Transplant. 2007 Jan;39(1):41-7. Epub 2006 Nov 20.

PMID:
17115062
18.

Autologous stem-cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT).

Jantunen E, Canals C, Attal M, Thomson K, Milpied N, Buzyn A, Ferrant A, Biron P, Crawley C, Schattenberg A, Luan JJ, Tilly H, Rio B, Wijermans PW, Dreger P, Sureda A; Lymphoma Working Party of the European Group for Blood and Marrow Transplantation (EBMT).

Ann Oncol. 2012 Jan;23(1):166-71. doi: 10.1093/annonc/mdr035. Epub 2011 Apr 5.

19.

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.

Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W.

Blood. 2005 Apr 1;105(7):2677-84. Epub 2004 Dec 9.

20.

Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.

Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH; Korean Multiple Myeloma Working Party.

Biol Blood Marrow Transplant. 2009 Apr;15(4):463-70. doi: 10.1016/j.bbmt.2008.12.512.

Items per page

Supplemental Content

Write to the Help Desk